These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 34711671)

  • 1. Treatment of Type 2 Diabetes and Obesity on the Basis of the Incretin System: The 2021 Banting Medal for Scientific Achievement Award Lecture.
    Holst JJ
    Diabetes; 2021 Nov; 70(11):2468-2475. PubMed ID: 34711671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.
    Skow MA; Bergmann NC; Knop FK
    Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two incretin hormones GLP-1 and GIP: comparison of their actions in insulin secretion and β cell preservation.
    Yabe D; Seino Y
    Prog Biophys Mol Biol; 2011 Nov; 107(2):248-56. PubMed ID: 21820006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RD Lawrence Lecture 2008: Targeting GLP-1 release as a potential strategy for the therapy of Type 2 diabetes.
    Gribble FM
    Diabet Med; 2008 Aug; 25(8):889-94. PubMed ID: 18959599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel extrapancreatic effects of incretin.
    Yamada Y; Tsukiyama K; Sato T; Shimizu T; Fujita H; Narita T
    J Diabetes Investig; 2016 Apr; 7 Suppl 1(Suppl 1):76-9. PubMed ID: 27186360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of chronic exposure of clonal β-cells to elevated glucose and free fatty acids on incretin receptor gene expression and secretory responses to GIP and GLP-1.
    Pathak V; Vasu S; Flatt PR; Irwin N
    Diabetes Obes Metab; 2014 Apr; 16(4):357-65. PubMed ID: 24164718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physiology of incretins and loss of incretin effect in type 2 diabetes and obesity.
    Opinto G; Natalicchio A; Marchetti P
    Arch Physiol Biochem; 2013 Oct; 119(4):170-8. PubMed ID: 23859800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The expanding incretin universe: from basic biology to clinical translation.
    Drucker DJ; Holst JJ
    Diabetologia; 2023 Oct; 66(10):1765-1779. PubMed ID: 36976349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incretin hormones and type 2 diabetes.
    Nauck MA; Müller TD
    Diabetologia; 2023 Oct; 66(10):1780-1795. PubMed ID: 37430117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity.
    Gault VA; Kerr BD; Harriott P; Flatt PR
    Clin Sci (Lond); 2011 Aug; 121(3):107-17. PubMed ID: 21332446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating glucose-dependent insulinotropic polypeptide and glucagon as key regulators of insulin secretion in the pancreatic islet.
    Lewandowski SL; El K; Campbell JE
    Am J Physiol Endocrinol Metab; 2024 Jul; 327(1):E103-E110. PubMed ID: 38775725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incretin actions beyond the pancreas: lessons from knockout mice.
    Yabe D; Seino Y
    Curr Opin Pharmacol; 2013 Dec; 13(6):946-53. PubMed ID: 24095602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incretin-based therapy of type 2 diabetes mellitus.
    Knop FK; Vilsbøll T; Holst JJ
    Curr Protein Pept Sci; 2009 Feb; 10(1):46-55. PubMed ID: 19275672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incretin dysfunction in type 2 diabetes: clinical impact and future perspectives.
    Ahrén B
    Diabetes Metab; 2013 May; 39(3):195-201. PubMed ID: 23643349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on incretin hormones.
    Phillips LK; Prins JB
    Ann N Y Acad Sci; 2011 Dec; 1243():E55-74. PubMed ID: 22545749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New therapeutic approach in patients with type 2 diabetes based on glucagon-like peptide 1 (GLP-1) and gastric inhibitory peptide (GIP)].
    Kluz J; Adamiec R
    Postepy Hig Med Dosw (Online); 2006; 60():15-23. PubMed ID: 16407790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The entero-insular axis: implications for human metabolism.
    Ranganath LR
    Clin Chem Lab Med; 2008; 46(1):43-56. PubMed ID: 18020966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The incretin system ABCs in obesity and diabetes - novel therapeutic strategies for weight loss and beyond.
    João AL; Reis F; Fernandes R
    Obes Rev; 2016 Jul; 17(7):553-72. PubMed ID: 27125902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GIP: no longer the neglected incretin twin?
    Kulkarni RN
    Sci Transl Med; 2010 Sep; 2(49):49ps47. PubMed ID: 20844284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GIP as a Therapeutic Target in Diabetes and Obesity: Insight From Incretin Co-agonists.
    Holst JJ; Rosenkilde MM
    J Clin Endocrinol Metab; 2020 Aug; 105(8):e2710-6. PubMed ID: 32459834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.